The multivariable logistic regression analysis determined that patients with EOSS stage 3 have a 2.94 adjusted odds ratio of 1-year complications vs. patients of lower stages (P less than .043).
“Although the patients with higher EOSS scores above 3 and … end-organ damage … may benefit from bariatric surgery, they inherently have higher postoperative risk,” Mr. Skulsky said. “We must take that into consideration.”
Among the limitations of the study, Mr. Skulsky acknowledged, were that it included only patients who had RYGB, that it had a bias toward patients with EOSS stage 2 score, and that it included no stage 4 patients. “They’re not commonly operated on,” he noted, “so we didn’t actually get to study the entire scoring system.”
The next step involves moving the analysis forward to the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database, Mr. Skulsky said. “The results that we found so far are pretty encouraging,” he said.
Mr. Skulsky had no financial relationships to disclose.
SOURCE: Skulsky SL et al. SAGES 2019, Session SS12.